BiotechTube

Bimatoprost SR + LUMIGAN

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Open-Angle Glaucoma

Conditions

Open-Angle Glaucoma, Ocular Hypertension

Trial Timeline

Jun 11, 2020 → May 14, 2022

NCT ID
NCT04285580

About Bimatoprost SR + LUMIGAN

Bimatoprost SR + LUMIGAN is a phase 3 stage product being developed by AbbVie for Open-Angle Glaucoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04285580. Target conditions include Open-Angle Glaucoma, Ocular Hypertension.

What happened to similar drugs?

5 of 18 similar drugs in Open-Angle Glaucoma were approved

Approved (5) Terminated (1) Active (12)
🔄Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)Mankind PharmaPhase 3
🔄A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mLSanten PharmaceuticalPhase 3
🔄Bimatoprost SRAbbViePhase 3
🔄Bimatoprost (SR)AbbViePhase 3
🔄Bimatoprost SR + Sham Bimatoprost SRAbbViePhase 3
🔄Preservative-Free Tafluprost + Comparator: timololMerckPhase 3
✅Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension + Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution + Subject's habitual PGA monotherapyNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04285580Phase 3Completed

Competing Products

20 competing products in Open-Angle Glaucoma

See all competitors
ProductCompanyStageHype Score
Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)Mankind PharmaPhase 3
40
DE-104 ophthalmic solution + DE-104 vehicleSanten PharmaceuticalPhase 2
35
DE-104 ophthalmic solution, low concentration + DE-104 ophthalmic solution, medium concentration + DE-104 ophthalmic solution, high concentration + DE-104 vehicleSanten PharmaceuticalPhase 2
35
A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mLSanten PharmaceuticalPhase 3
40
Bimatoprost SRAbbViePhase 3
44
AGN-193408 SR + AGN-193408 SRAbbViePhase 1/2
39
Bimatoprost (SR)AbbViePhase 3
40
Bimatoprost Sustained Release ImplantAbbViePre-clinical
26
Bimatoprost SR + Sham Bimatoprost SRAbbViePhase 3
40
Preservative-Free Tafluprost + Comparator: timololMerckPhase 3
40
Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension + Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution + Subject's habitual PGA monotherapyNovartisApproved
43
Placebo + RO5093151RochePhase 2
35
0.01% RO7058584 + 0.1% RO7058584 + 1% RO7058584 + Matching Placebo + Latanoprost 0.005%RochePhase 1
29
XalacomPfizerPhase 3
40
XalatanPfizerPhase 2
27
LatanoprostPfizerApproved
43
PF-04217329 - Lowest Dose + PF-04217329 - Low Dose + PF-04217329 - Middle Dose + PF-04217329 - High Middle Dose + PF-04217329 - High Dose + PF-4217329 - Highest Dose + PF-04217329 - Vehicle + Latanoprost Vehicle + PF-04217329 - Low Dose + Latanoprost Vehicle + PF-04217329 - Middle Dose + Latanoprost Vehicle + PF-04217329 - High Dose + Latanoprost 0.005% + PF-04217329 - Low Dose + Latanoprost 0.005% + PF-04217329 - Middle Dose + Latanoprost 0.005% + PF-04217329 - High Dose + Latanoprost 0.005% + PF-04217329 - VehiclePfizerPhase 2
35
XalacomPfizerPre-clinical
26
Xalacom + Xalatan + TimololPfizerPhase 3
40
PF-04217329 + latanoprost vehicle + PF-04217329 + latanoprostPfizerPhase 2
35